Dexamethasone doses in patients with COVID ‐19 and hypoxia: A systematic review and meta‐analysis
Acta Anaesthesiologica Scandinavica · 2024-02 · 68 (2) · 146-166
DOI: 10.1111/aas.14346 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Acta Anaesthesiologica Scandinavica, online erschienen am 26.10.2023. Verfasst von Marie Warrer Munch und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research Applied Research Collaboration West, Rigshospitalet's Research Council, Weston NHS Foundation Trust.
Abstract (Originalsprache)
Background
The optimal dose of dexamethasone for severe/critical COVID‐19 is uncertain. We compared higher versus standard doses of dexamethasone in adults with COVID‐19 and hypoxia.
Methods
We searched PubMed and trial registers until 23 June 2023 for randomised clinical trials comparing higher (>6 mg) versus standard doses (6 mg) of dexamethasone in adults with COVID‐19 and hypoxia. The primary outcome was mortality at 1 month. Secondary outcomes were mortality closest to 90 days; days alive without life support; and the occurrence of serious adverse events/reactions (SAEs/SARs) closest to 1 month. We assessed the risk of bias using the Cochrane RoB2 tool, risk of random errors using trial sequential analysis, and certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results
We included eight trials (2478 participants), of which four (1293 participants) had low risk of bias. Higher doses of dexamethasone probably resulted in little to no difference in mortality at 1 month (relative risk [RR] 0.97, 95% CI: 0.79–1.19), mortality closest to Day 90 (RR 1.01, 95% CI: 0.86–1.20), and SAEs/SARs (RR 1.00, 95% CI: 0.97–1.02). Higher doses of dexamethasone probably increased the number of days alive without invasive mechanical ventilation and circulatory support but had no effect on days alive without renal replacement therapy.
Conclusions
Based on low to moderate certainty evidence, higher versus standard doses of dexamethasone probably result in little to no difference in mortality, SAEs/SARs, and days alive without renal replacement therapy, but probably increase the number of days alive without invasive mechanical ventilation and circulatory support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark.
- Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Simulation Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 2nd Department of Anaesthesiology University Hospital Brno, Brno, Czech Republic.
- Department of Internal Medicine and Cardiology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
ORCID-Profile: Marie Warrer Munch, Anders Granholm, Jan Maláska, Sheila Nainan Myatra, Anders Perner, Morten Hylander Møller
Förderung
- National Institute for Health Research Applied Research Collaboration West
- Rigshospitalet's Research Council
- Weston NHS Foundation Trust
- Department of Health and Social Care
- MEYS LRI CZECRIN
- FNBr
Zitieren
APA
Munch, M. W., Granholm, A., Maláska, J., Stašek, J., Rodriguez, P. O., Pitre, T., Wilson, R., Savović, J., Rochwerg, B., Svobodnik, A., Kratochvíl, M., Taboada, M., Jha, V., Vijayaraghavan, B. K. T., Myatra, S. N., Venkatesh, B., Perner, A., & Møller, M. H. (2024). Dexamethasone doses in patients with COVID ‐19 and hypoxia: A systematic review and meta‐analysis. Acta Anaesthesiologica Scandinavica, 68(2), 146-166. https://doi.org/10.1111/aas.14346
Vancouver
Munch MW, Granholm A, Maláska J, Stašek J, Rodriguez PO, Pitre T, et al. Dexamethasone doses in patients with COVID ‐19 and hypoxia: A systematic review and meta‐analysis. Acta Anaesthesiologica Scandinavica. 2024;68(2):146-166. doi:10.1111/aas.14346
BibTeX
@article{Munch2024,
author = {Munch, Marie Warrer and Granholm, Anders and Maláska, Jan and Stašek, Jan and Rodriguez, Pablo O and Pitre, Tyler and Wilson, Rebecca and Savović, Jelena and Rochwerg, Bram and Svobodnik, Adam and Kratochvíl, Milan and Taboada, Manuel and Jha, Vivekanand and Vijayaraghavan, Bharath Kumar Tirupakuzhi and Myatra, Sheila Nainan and Venkatesh, Balasubramanian and Perner, Anders and Møller, Morten Hylander},
title = {Dexamethasone doses in patients with COVID ‐19 and hypoxia: A systematic review and meta‐analysis},
journal = {Acta Anaesthesiologica Scandinavica},
year = {2024},
volume = {68},
number = {2},
pages = {146--166},
doi = {10.1111/aas.14346}
}
EUVIMED